Öppna denna publikation i ny flik eller fönster >>Visa övriga...
2019 (Engelska)Ingår i: Medicinal Chemistry Research, ISSN 1054-2523, E-ISSN 1554-8120, Vol. 28, nr 3, s. 380-386Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Androgen receptor (AR) signaling is often activated in prostate cancer (PCa) cells, and blockage of this signaling by AR antagonists is an important strategy in PCa therapy. In this study, we designed and synthesized a series of 2-(5-methyl-1H-pyrazol-1-yl) acetamide derivatives, and evaluated their biological activities. AR luciferase reporter assay revealed compound 6f (59.7%) as a potent AR antagonist. Some compounds in this series showed higher anti-proliferative activity against LNCaP cells than Bicalutamide (IC50=35.0M), especially 6g with IC50 value of 13.6 mu M.
Ort, förlag, år, upplaga, sidor
Springer, 2019
Nyckelord
Androgen receptor, Prostate cancer, Antagonists, Pyrazole derivatives
Nationell ämneskategori
Farmakologi och toxikologi Cancer och onkologi
Identifikatorer
urn:nbn:se:oru:diva-73118 (URN)10.1007/s00044-019-02291-y (DOI)000459449600013 ()2-s2.0-85060553900 (Scopus ID)
Forskningsfinansiär
KK-stiftelsen, 201550084
Anmärkning
Funding Agencies:
National Natural Science Foundation of China 21272140
Key Research and Development Project of Shandong Province 2017CXGC1401
2019-03-142019-03-142019-03-14Bibliografiskt granskad